Table 2.
Intraocular pressure-related events and cataract surgery after the fluocinolone acetonide implant and time-to-event analyses
| All eyes (n = 221) | France (n = 141) | Germany (n = 46) | Portugal (n = 28) | Italy (n = 6) | |
|---|---|---|---|---|---|
| Emergent IOP-lowering medication | |||||
| None | 166 (75.2%) | 118 (83.7%) | 20 (43.5%) | 23 (82.2%) | 5 (83.3%) |
| Single therapy | 25 (11.3%) | 6 (4.3%) | 16 (34.8%) | 2 (7.1%) | 1 (16.7%) |
| Dual therapy | 24 (10.8%) | 14 (9.9%) | 7 (15.2%) | 3 (10.7%) | 0 |
| Triple therapy or more | 6 (2.7%) | 3 (2.1%) | 3 (6.5%) | 0 | 0 |
| Mean time to event (months) | 7.9 (7.4) | 4.0 (3.5) | 11.7 (8.1) | 2.8 (2.4) | |
| Laser trabeculoplasty | 1 (0.5%) | 1 (0.7%) | 0 | 0 | 0 |
| MIGS | 1 (0.5%) | 1 (0.7%) | 0 | 0 | 0 |
| Incisional IOP-lowering surgery | 0 | 0 | 0 | 0 | 0 |
| Cataract surgery | 23 (10.4%) | 0 | 22 (47.8%) | 1 (3.5%) | 0 |
| Mean time to event (months) | 15.2 (7.6) | 14.7 (7.3) | 27 | ||
Continuous variables are displayed as mean (SD) and time-to-event analyses are presented in months and were not performed for laser trabeculoplasty or MIGS, as the number of events was very small. Categorical variables are displayed as number (percentage)
IOP intraocular pressure, MIGS minimally invasive glaucoma surgery